Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.


:Naltrexone-bupropion is a recently approved drug combination for chronic weight management. In this article, we discuss the rationale for its use as a combination followed by a comprehensive review of safety and efficacy data from major preclinical, phase II and III clinical trials.


Ali KF,Shukla AP,Aronne LJ




Has Abstract


2016-01-01 00:00:00












  • Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.

    abstract::Neuroblastoma (NB) is the most common extra cranial solid tumor of childhood, with 60% of patients presenting with high risk (HR) NB by means of clinical, pathological and biological features. The 5-year survival rate for HR-NB remains below 40%, with the majority of patients suffering relapse from chemorefractory tum...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Mora J

    更新日期:2016-01-01 00:00:00

  • Efficacy and safety of etoricoxib in the treatment of osteoarthritis.

    abstract::Osteoarthritis is a progressive disease that affects millions of people worldwide, but for which there are no curative options and indeed a limited number of medical treatment options. The American College of Rheumatology recommendations suggest administering either a traditional NSAID or a COX-2-selective inhibitor f...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章


    authors: Sebba A

    更新日期:2008-05-01 00:00:00

  • Upcoming drugs for the treatment of preeclampsia in pregnant women.

    abstract::Preeclampsia is a pregnancy-specific multisystem disorder, complicating 2 - 8% of pregnancies, and represents a leading cause of maternal and perinatal morbidity and mortality. Recent investigations have elucidated the understanding of its underlying pathogenic mechanisms. However, despite these advances, therapeutic ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章


    authors: Ornaghi S,Paidas MJ

    更新日期:2014-09-01 00:00:00

  • Clinical pharmacology of linezolid: an oxazolidinone antimicrobial agent.

    abstract::The oxazolidinones are a new class of antibiotics whose mechanism of action is the inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit. Linezolid is the first member of this class of antibiotics to be approved by the US FDA and other regulatory bodies for the treatment of infections cause...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章


    authors: Tan TQ,Yogev R

    更新日期:2008-07-01 00:00:00

  • Pharmacological management of diabetic dyslipidemia.

    abstract:INTRODUCTION:Diabetes mellitus is associated with increased cardiovascular disease (CVD) risk. Areas covered: Main goal of hypolipidemic treatment in diabetic patients is low-density lipoprotein cholesterol (LDL-C) lowering with the use of statins. Addition of ezetimibe is useful in diabetic patients who cannot achieve...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Filippatos TD,Florentin M,Georgoula M,Elisaf MS

    更新日期:2017-02-01 00:00:00

  • Lucinactant for the prevention of respiratory distress syndrome in premature infants.

    abstract::Respiratory distress syndrome (RDS) is the leading cause of neonatal morbidity and mortality in premature infants. It is caused by surfactant deficiency and lung immaturity. Lucinactant is a synthetic surfactant containing sinapultide, a bioengineered peptide mimic of surfactant-associated protein B. A meta-analysis o...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Jordan BK,Donn SM

    更新日期:2013-03-01 00:00:00

  • Adverse reactions to oncologic drugs: spontaneous reporting and signal detection.

    abstract::Oncology is one of the areas of medicine with the most active research being conducted on new drugs. New pharmacological entities frequently enter the clinical arena, and therefore, the safety profile of anticancer products deserves continuous monitoring. However, only very severe and (unusual) suspected adverse drug ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Tuccori M,Montagnani S,Capogrosso-Sansone A,Mantarro S,Antonioli L,Fornai M,Blandizzi C

    更新日期:2015-01-01 00:00:00

  • Novel pharmaceuticals in the management of postoperative pain.

    abstract::Novel pharmaceutical advances in postoperative pain management include both non-opioid adjuvants as well as opioid analgesics. Optimizing postoperative analgesics includes improving onset of action, matching duration of analgesia to the setting of use, and minimizing adverse events. To improve on the current standard ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 社论


    authors: Palmer P

    更新日期:2015-01-01 00:00:00

  • Secukinumab (AIN-457) for the treatment of Psoriasis.

    abstract::Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Jaleel T,Elmets C,Weinkle A,Kassira S,Elewski B

    更新日期:2016-01-01 00:00:00

  • An update on repurposed medications for the treatment of drug-resistant tuberculosis.

    abstract:INTRODUCTION:Drug-resistant forms of tuberculosis are a major public health problem with a serious global impact. Although there have recently been two new drugs introduced for the treatment of drug-resistant TB (bedaquiline and delamanid), the current therapeutic armamentarium is limited. Because treatment of drug-res...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章


    authors: Mafukidze A,Harausz E,Furin J

    更新日期:2016-10-01 00:00:00

  • Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences.

    abstract::Sodium-glucose co-transporter-2 inhibitors (SGLT-2I) are recently approved class of anti-hyperglycaemic agents for the treatment of type 2 diabetes mellitus (T2DM). SGLT-2I inhibits renal glucose reabsorption, thereby ensuing urinary glucose excretion in a dose-dependent manner. This caloric loss and osmotic diuresis,...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Singh AK,Singh R

    更新日期:2016-01-01 00:00:00

  • Crofelemer for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy.

    abstract::Chronic diarrhea remains a common condition that affects people infected with human immunodeficiency virus (HIV) despite the widespread use of potent antiretroviral therapy. It is important that providers control this condition, as the persistence of diarrhea affects the quality of life of patients and may contribute ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Castro JG,Chin-Beckford N

    更新日期:2015-01-01 00:00:00

  • Effects of red wine on established markers of arterial structure and function in human studies: current knowledge and future research directions.

    abstract::Evidence from observational studies suggests that mild-to-moderate consumption of red wine is associated with reduced cardiovascular morbidity and mortality. Various individual chemical components of red wine also show salutary effects on vascular homeostasis, that is, enhanced endothelial function and arterial disten...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章


    authors: Mangoni AA,Stockley CS,Woodman RJ

    更新日期:2013-11-01 00:00:00

  • Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis.

    abstract::Introduction: Primary endpoints and inclusion/exclusion criteria of biologics and small oral molecules for psoriasis treatment have been evolving due to a better understanding of the pathogenesis and potential risks.Areas covered: We analyzed the designs of key phase 3 pivotal trials of all biologics and small oral mo...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Hsu SH,Tsai TF

    更新日期:2020-03-01 00:00:00

  • Clinical pharmacology in HIV cure research - what impact have we seen?

    abstract::Introduction: Combined antiretroviral therapy (cART) has transformed an inexorably fatal disease into a chronic pathology, shifting the focus of research from the control of viral replication to the possibility of HIV cure. Areas covered: The present review assesses the principal pharmacological strategies that have b...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Giacomelli A,de Rose S,Rusconi S

    更新日期:2019-01-01 00:00:00

  • Pharmacological treatment of pediatric Gaucher disease.

    abstract:INTRODUCTION:Gaucher disease (GD) is an autosomal recessive disorder resulting from the deficiency of the lysosomal enzyme glucocerebrosidase (b-glucosidase), associated with varying degrees of visceral, bone and central nervous system pathology, leading to wide phenotypic diversity. Response to therapy and clinical ou...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Gupta P,Pastores G

    更新日期:2018-12-01 00:00:00

  • Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks.

    abstract:INTRODUCTION:Therapeutic efficiency of NSAID is handicapped by ongoing discussion of cardiovascular (CV) safety. Areas covered: We update meta-analyses on NSAIDs in patients with and without cardiovascular (CV) diseases and analyse the association between NSAIDs and cardiovascular events in patients with inflammation. ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Zingler G,Hermann B,Fischer T,Herdegen T

    更新日期:2016-11-01 00:00:00

  • Three-month paliperidone palmitate - a new treatment option for schizophrenia.

    abstract:INTRODUCTION:Long-acting injectable antipsychotics (LAIAs) were introduced to improve treatment adherence and tolerability of oral formulations. After risperidone was introduced as the first long-acting injectable second-generation antipsychotic, during the last five years olanzapine pamoate, once-monthly paliperidone ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Bernardo M,Bioque M

    更新日期:2016-07-01 00:00:00

  • Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis.

    abstract:INTRODUCTION:Anti-vascular endothelial growth factor (VEGF) therapy has become the most commonly used treatment for macular edema secondary to retinal vein occlusion (RVO). Although its superior efficacy as compared to other interventions has been proven, there is a lack of evidence for relative efficacy among anti-VEG...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,meta分析,评审


    authors: Sangroongruangsri S,Ratanapakorn T,Wu O,Anothaisintawee T,Chaikledkaew U

    更新日期:2018-09-01 00:00:00

  • Use of strong opioids for chronic pain in osteoarthritis: an insight into the Latin American reality.

    abstract:INTRODUCTION:Osteoarthritis is the most common cause of arthritis and one of the main causes of chronic pain. Although opioids are frequently employed for chronic pain treatment, their usage for osteoarthritis pain remains controversial due to the associated adverse effects. Most guidelines reserve their use for refrac...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Ruiz Iban MA,Benavides J,Forero JP,Bittelman S,Martinez R,Mite MA,Diaz Heredia J,Ulloa S,Lizárraga Ferrand MM

    更新日期:2018-01-01 00:00:00

  • Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.

    abstract:INTRODUCTION:Induction chemotherapy based on anthracyclines and cytarabine (Ara-C) combination remains the standard of care for acute myeloid leukemia (AML) patients who are considered candidate for intensive and curative approaches. However, the toxicity of this regimen is high, with disappointing clinical outcomes am...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章


    authors: Megías-Vericat JE,Martínez-Cuadrón D,Sanz MÁ,Poveda JL,Montesinos P

    更新日期:2019-03-01 00:00:00

  • Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.

    abstract::Introduction: In September of 2018, the United States Federal Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for advanced cutaneous squamous cell carcinoma (CSCC). Cemiplimab is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1). Cemiplimab blocks T-cell ina...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Ahmed SR,Petersen E,Patel R,Migden MR

    更新日期:2019-10-01 00:00:00

  • Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy.

    abstract::Magnetic nanoparticles (MNPs) represent a promising nanomaterial for the targeted therapy and imaging of malignant brain tumors. Conjugation of peptides or antibodies to the surface of MNPs allows direct targeting of the tumor cell surface and potential disruption of active signaling pathways present in tumor cells. D...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Wankhede M,Bouras A,Kaluzova M,Hadjipanayis CG

    更新日期:2012-03-01 00:00:00

  • Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.

    abstract::In the management of chronic obstructive pulmonary disease (COPD), there is an unmet medical need for effective bronchodilator treatments that not only have a fast onset of action, but also a long duration of action and are delivered using a simple, easy-to-use device. Long-acting muscarinic antagonists such as glycop...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Molimard M,D'Andrea P

    更新日期:2013-09-01 00:00:00

  • Management of patients with inflammatory bowel disease and spondyloarthritis.

    abstract:INTRODUCTION:More than half of the patients with inflammatory bowel disease (IBD) experience at least one extra-intestinal manifestation (EIM). The most common EIM in patients with IBD is spondyloarthritis (SpA). Microscopic intestinal inflammation is documented in almost 50% of the patients with SpA. Areas covered: We...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Pouillon L,Bossuyt P,Vanderstukken J,Moulin D,Netter P,Danese S,Jouzeau JY,Loeuille D,Peyrin-Biroulet L

    更新日期:2017-12-01 00:00:00

  • Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings.

    abstract::The QT interval from the ECG cannot be measured precisely. The relationship of the QT interval to the RR interval within individuals across time and different RR values, and across individuals eludes complete understanding. Intrinsic beat-to-beat variability in QT interval corrected for heart rate (QTc interval) is no...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章


    authors: Beasley CM Jr,Dmitrienko A,Mitchell MI

    更新日期:2008-11-01 00:00:00

  • The genetics of vascular incidents associated with second-generation antipsychotic administration.

    abstract::Second-generation antipsychotics (SGA) have been associated with risk of stroke in elderly patients, but the molecular and genetic background under this association has been poorly investigated. The aim of the present study was to prioritize a list of genes with an SGA altered expression in order to characterize the g...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Cocchi E,Drago A,de Ronchi D,Serretti A

    更新日期:2014-01-01 00:00:00

  • Omega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future.

    abstract:INTRODUCTION:Large-scale epidemiological studies on Greenlandic, Canadian and Alaskan Eskimos have examined the health benefits of omega-3 fatty acids consumed as part of the diet, and found statistically significant relative reduction in cardiovascular risk in people consuming omega-3 fatty acids. Areas covered: This ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Watanabe Y,Tatsuno I

    更新日期:2017-08-01 00:00:00

  • Hydrogen sulfide in the endocrine and reproductive systems.

    abstract::Hydrogen sulfide (H(2)S) is now considered a member of a group of signaling molecules termed 'gasotransmitters'. H(2)S has been shown to be generated in the endocrine and reproductive organs and elicits various actions. H(2)S modulates insulin secretion in pancreatic islets. Adipose tissues have the ability to produce...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Zhu XY,Gu H,Ni X

    更新日期:2011-01-01 00:00:00

  • G-quadruplex interacting small molecules and drugs: from bench toward bedside.

    abstract::G-quadruplexes are non-Watson-Crick four-stranded nucleic acid structures. Recent evidence points toward their existence in vivo and their implication in various biological processes. Over the past two decades, small molecules have been developed to specifically and selectively target these structures in order to diss...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Müller S,Rodriguez R

    更新日期:2014-09-01 00:00:00